Gilbert’s question is reasonable insofar as generic Copaxone (if approved) will surely have a lower patient copayment and a lower ASP than (branded) thrice-weekly Copaxone.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.